Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.43 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | WIZ | O95785 | 1/20 | 0.43 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22685753 | 0.90 | CRBN (0.65) | CRBNCSNK1A1IKZF1DDB1GSPT1 | |
| SCHEMBL22685474 | 0.84 | CRBN (0.49) | CRBNCSNK1A1IKZF1DDB1GSPT1 | |
| Sontigidomide SCHEMBL22685741 | 0.84 | CRBN (0.62) | CRBNCSNK1A1IKZF1DDB1GSPT1 | |
| SCHEMBL22685525 | 0.83 | CRBN (0.58) | CRBNCSNK1A1IKZF1DDB1GSPT1 | |
| SCHEMBL22685483 | 0.80 | CRBN (0.52) | CRBNCSNK1A1IKZF1DDB1IKZF3 | |
| SCHEMBL22685470 | 0.79 | CRBN (0.69) | CRBNCSNK1A1IKZF1DDB1GSPT1 | |
| SCHEMBL22685463 | 0.79 | CRBN (0.56) | CRBNCSNK1A1DDB1GSPT1CYP2C19 | |
| SCHEMBL22685519 | 0.79 | CRBN (0.71) | CRBNCSNK1A1IKZF1DDB1GSPT1 | |
| SCHEMBL22685477 | 0.78 | CRBN (0.63) | CRBNCSNK1A1IKZF1DDB1IKZF3 | |
| SCHEMBL25252486 | 0.77 | CRBN (0.53) | CRBNCSNK1A1IKZF1DDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| US-20220298172-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-09-22 | — | — | US | claimed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | claimed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3976623-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220298172-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3976623-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020242960-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020242960-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298172-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HSP90B1, EIF4EBP1, SERPINA6 | CRBN 358/4885CSNK1A1 520/4885IKZF1 2328/4885 |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | HSP90B1, EIF4EBP1, SERPINA6 | CRBN 358/4885CSNK1A1 520/4885IKZF1 2328/4885 |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HSP90B1, EIF4EBP1, SERPINA6 | CRBN 358/4885CSNK1A1 520/4885IKZF1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.